Asia-Pacific Cardiac Stents Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Cardiac Stents Market Size

• The Asia-Pacific Cardiac Stents Market size was valued at USD 1.8 billion in 2024 and is expected to reach USD 3.78 billion by 2032, at a CAGR of 9.7 % during the forecast period
• Growth in this market is attributed to rising prevalence of cardiovascular diseases, increasing preference for minimally invasive procedures, and advancements in stent technology.

Cardiac Stents Market Analysis

• Cardiac stents are small mesh tubes inserted into narrowed or blocked coronary arteries to improve blood flow and prevent heart attacks, commonly used in angioplasty.
• The market is witnessing growth due to the rising geriatric population, poor lifestyle habits, and an increase in coronary artery disease cases across Asia-Pacific.
• The China holds the largest market share of 26.78% due to favorable reimbursement policies, technological innovations, and a high number of PCI (percutaneous coronary intervention) procedures.
• China is expected to hold the largest share in the Asia-Pacific cardiac stents market due to its vast population, increasing prevalence of coronary artery disease, and significant investments in healthcare infrastructure. The government’s focus on improving cardiovascular care and the rising adoption of advanced stent technologies further boost market growth.
• India is expected to witness rapid growth during the forecast period, driven by the increasing incidence of cardiovascular diseases, growing healthcare awareness, and expanding urban healthcare facilities. Affordable healthcare services and rising medical tourism also contribute to the market expansion.
• The drug-eluting stents (DES) segment with 43.15% is expected to be the fastest-growing segment in the Asia-Pacific cardiac stents market, driven by its superior clinical outcomes in reducing restenosis and improving long-term vessel patency. Despite the availability of bare-metal stents (BMS) and bioresorbable vascular scaffolds (BVS), DES continues to gain rapid adoption due to ongoing advancements in stent coatings and drug formulations that enhance safety and efficacy. Increasing awareness among cardiologists about the benefits of DES, coupled with expanding healthcare infrastructure and growing patient volumes in countries like China and India, is accelerating its uptake. The segment’s ability to reduce repeat interventions makes it a preferred choice in both urban and emerging markets within the region.

Report Scope and Cardiac Stents Market Segmentation       

Cardiac Stents Market Trends

“Advancing Cardiovascular Care and Innovations in Stent Technologies”

• The growing prevalence of cardiovascular diseases across Asia-Pacific, particularly coronary artery disease, is significantly driving the demand for advanced cardiac stents, including drug-eluting stents (DES), bare-metal stents (BMS), and bioresorbable scaffolds.
• Increasing investments in minimally invasive cardiac procedures are boosting the adoption of next-generation stents, which offer enhanced biocompatibility, reduced restenosis rates, and improved long-term patient outcomes.

• For instance, medical device companies in China and India are developing drug-eluting stents with biodegradable polymers to address post-procedural complications and support vessel healing.
• Rising use of cardiac stents in both clinical and outpatient settings is supported by regulatory harmonization, robust reimbursement frameworks, and clinical data validation across Asia-Pacifica markets.
• Technological advancements, including stent coating innovations, imaging-guided implantation, and patient-specific stent design, are complementing—not replacing—traditional stenting methods, ensuring performance reliability in both routine and complex cases growth.

Cardiac Stents Market Dynamics

Driver

“Rising Prevalence of Coronary Artery Disease and Lifestyle Disorders”

• Cardiovascular diseases are the leading cause of death in Asia-Pacific, largely driven by sedentary lifestyles, obesity, hypertension, and diabetes
• As coronary artery disease continues to rise, so does the demand for effective interventions like stents
• A growing aging population further contributes to increased incidence and procedural volumes

For instance,

• Cardiovascular diseases, driven by sedentary lifestyles, obesity, and hypertension, are the leading cause of death in Asia-Pacific. With 805,000 heart attacks annually, demand for stents and interventional solutions is rising. Increased public awareness and routine screening are also supporting early diagnosis and treatment, fueling market growth.
• Increased public awareness and routine cardiovascular screening are further fueling the early diagnosis and treatment, supporting market growth

Opportunity

“Emergence of Bioabsorbable Stents to Replace Traditional Implants”

• Bioabsorbable stents represent a paradigm shift, offering temporary scaffolding without long-term foreign body presence
•  These stents dissolve after healing, reducing risks associated with permanent metal implants such as inflammation or thrombosis
• Market players are investing in R&D to enhance radial strength, degradation rates, and drug-delivery mechanisms

For instance,

• By 2030, biologics are expected to comprise over 30% of pharmaceutical sales, driving demand for Cardiac Stents that ensure sterility, dosing accuracy, and ease of use. Their compatibility with injectable biologics makes them vital for delivering high-value therapies in areas like oncology, immunology, and chronic disease management.

Such advancements may help address safety concerns and improve outcomes, especially in younger and active patients

Restraint/Challenge

“High Cost and Regulatory Hurdles Slowing Market Penetration”

• Despite technological advances, cardiac stents remain expensive, with costs ranging from several hundred to thousands of dollars depending on the type
• Reimbursement issues and pricing pressures further affect market accessibility, particularly in middle-income settings
• Moreover, regulatory approvals for new-generation stents require robust clinical evidence, delaying product launches

For instance,

• Cardiac Stents, while convenient, face safety issues such as contamination, glass breakage, and material incompatibility—especially with biologics. Recalls due to such defects raise concerns for manufacturers. Ensuring consistent quality, integrity, and regulatory compliance adds complexity and costs, potentially impacting product reliability, patient safety, and overall market confidence.

These financial and regulatory complexities pose challenges for both established and emerging players in the Asia-Pacific market.

Cardiac Stents Market Scope

The market is segmented on the basis of material, type, Mode of delivery, end user.

In 2025, the Drug-Eluting Stents segment is projected to dominate the market with the largest share in type segment

Drug-eluting stents (DES) are anticipated to lead the Asia-Pacific cardiac stents market with over 43.18% share in 2025. Their superior efficacy, reduced restenosis rates, and long-term safety compared to bare-metal stents drive this dominance. Increasing preference for DES in percutaneous coronary interventions supports sustained growth and widespread adoption across clinical practices.

The Metallic Stents segment is expected to account for the largest share during the forecast period in material segment

In 2025, metallic stents, particularly cobalt-chromium and platinum-chromium types, will dominate with the largest share, accounting for 31.34%, due to their excellent radial strength and clinical success. These stents are preferred in high-pressure environments, including complex lesions. Continued innovation in alloy composition and surface coatings further enhances their market position.

Cardiac Stents Market Regional Analysis

“China Holds the Largest Share in the Cardiac Stents Market”

• The China dominates the cardiac stents market in Asia-Pacific due to advanced healthcare systems, high interventional cardiology procedure volumes, and strong regulatory frameworks
• Leading companies are headquartered in the China, contributing to continuous innovation, product launches, and market maturity
• Favorable reimbursement policies, growing prevalence of cardiovascular risk factors, and increased focus on patient-centric care support robust market expansion
• Public-private initiatives for heart health awareness and improved diagnostic networks further accelerate market development

“India is Projected to Register the Highest CAGR in the Cardiac Stents Market”

• India is witnessing steady growth due to investments in cardiac care, government coverage of essential interventions, and focus on value-based care
• India is progressing with increased public-private collaborations to improve access to interventional cardiology
• The entry of international stent manufacturers and localized manufacturing efforts are boosting competitiveness and affordability in these countries

Cardiac Stents Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Abbott Laboratories (U.S.)
• Medtronic (Ireland)
• Boston Scientific Corporation (U.S.)
• Terumo Corporation (Japan)
• MicroPort Scientific Corporation (China)
• B. Braun Melsungen AG (Germany)
• Biosensors International Group (Singapore)
• KOB Medical Textiles Co., Ltd. (China)
• Tokushu Textile Co., Ltd. (Japan)
• Daoseal Co., Ltd. (South Korea)
• Medi-Tech Devices Pvt. Ltd. (India)
• Kanghui Medical Innovation Co., Ltd. (China)
• Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (China)
• Meril Life Sciences (India)

Latest Developments in Asia-Pacific Cardiac Stents Market

• In March 2025, Abbott announced successful trials for a next-generation bioabsorbable stent system with improved scaffold design and enhanced drug-elution profile
• In January 2025, Boston Scientific received FDA approval for its Synergy XD DES, an enhanced version with better flexibility and precision placement in tortuous vessel
•  In October 2024, Medtronic launched a cobalt-chromium DES with a novel antiproliferative agent aimed at reducing late-stage thrombosis and improving long-term patency 

SKU-1546